Factor IX: Insights from knock-out and genetically engineered mice.
The study of coagulation factors has been rapidly advanced by studies performed in genetically engineered mouse strains. Investigation of factor IX (FIX) has benefited from excellent gene-deleted mouse models that recapitulate many of the features of human haemophilia B. Moreover, advanced positional cloning techniques and availability of technology to allow not only knock-out mice, but also knock-in and knock-down mice, provide new opportunities to observe genotype-phenotype and structure-function correlations regarding FIX, as well as the interaction of FIX with inflammatory, immune, and tissue repair systems. In this paper, available FIX knock-out mice and additional haemophilia B mouse models are reviewed specifically in regards to observations these models have facilitated concerning:factor IX gene expression and factor IX protein pharmacokinetics; the role of FIX in haemostasis, thrombosis and wound healing; insights into coagulation FIX arising out of gene therapy applications in haemophilia mouse models; immunology of tolerance or loss of tolerance of FIX and inhibitor antibody formation.
Department of Pediatrics, Hematology/Oncology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599-7352, USA. Paul_Monahan@med.unc.edu
Paul E
PE
Monahan
D000818:Animals; D004195:Disease Models, Animal; D005164:Factor IX / Q000235:genetics* / Q000276:immunology / Q000378:metabolism; D015316:Genetic Therapy; D002836:Hemophilia B / Q000235:genetics* / Q000276:immunology / Q000628:therapy*; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic
D005164:Factor IX